For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Biotech’s balancing act amid Covid-19 delays
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Clinical trial delays become reality as Covid-19 risk spreads
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Nektar’s clearing event clears away $500m
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
